Brain pharmacokinetics of a nonpeptidic corticotropin-releasing factor receptor antagonist

被引:47
作者
Keller, C [1 ]
Bruelisauer, A [1 ]
Lemaire, M [1 ]
Enz, A [1 ]
机构
[1] Novartis Pharma AG, CH-4002 Basel, Switzerland
关键词
D O I
10.1124/dmd.30.2.173
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Corticotropin-releasing factor (CRF) is known to play an important role in the body response to stress. Butyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-ethylamine (CP-154,526) is a CRF1 antagonist showing anxiolytic activities in rats in behavioral models, suggesting that CP-154,526 crosses the blood-brain barrier. However, there is no direct evidence for this. This study determined the pharmacokinetic profile of CP-154,526 in rats after i.v. and p.o. application. After i.v. bolus, the concentration declined in a biphasic manner, the first half-life being 0.9 h and the terminal one being 51 h. Systemic clearance was 36 ml/min/kg, and the volume of distribution was 105 l/kg. Oral bioavailability reached 27%. To study brain pharmacokinetics, rats were given a single dose of CP-154,526 p.o. or i.v. and sacrificed after different post-treatment times. Plasma, cortex, striatum, hypothalamus, hippocampus, and cerebellum concentrations were measured. After i.v. bolus, maximal brain concentration was reached after 20 min. The hypothalamus displayed significantly lower concentrations compared with the other brain tissues. In the p.o. study, the maximal plasma concentration was reached after 30 min, whereas the maximal brain concentration was observed after 1 h and remained stable until 2 h post-treatment, without significant differences between the brain tissues. The unidirectional brain extraction ratio was 27 and 9% at vascular concentrations of 0.08 and 16 nmol/ml, respectively. These results demonstrate a large brain penetration of CP-154,526 after i.v. and p.o. applications and a comparable distribution among the brain regions, except for the hypothalamus, which displayed lower concentrations after i.v. bolus.
引用
收藏
页码:173 / 176
页数:4
相关论文
共 15 条
[1]  
Arborelius L, 2000, J PHARMACOL EXP THER, V294, P588
[2]   Corticotrophin-releasing factor receptors: From molecular biology to drug design [J].
Chalmers, DT ;
Lovenberg, TW ;
Grigoriadis, DE ;
Behan, DP ;
DeSouza, EB .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1996, 17 (04) :166-172
[3]  
CHALMERS DT, 1995, J NEUROSCI, V15, P6340
[4]   Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: A centrally active corticotropin-releasing factor(1) receptor antagonist [J].
Chen, YL ;
Mansbach, RS ;
Winter, SM ;
Brooks, E ;
Collins, J ;
Corman, ML ;
Dunaiskis, AR ;
Faraci, WS ;
Gallaschun, RJ ;
Schmidt, A ;
Schulz, DW .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (11) :1749-1754
[5]  
Griebel G, 1998, PSYCHOPHARMACOLOGY, V138, P55
[6]   Physiological and neurochemical aspects of corticotropin-releasing factor actions in the brain: The role of the locus coeruleus [J].
Lehnert, H ;
Schulz, C ;
Dieterich, K .
NEUROCHEMICAL RESEARCH, 1998, 23 (08) :1039-1052
[7]   A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity [J].
Lundkvist, J ;
Chai, Z ;
Teheranian, R ;
Hasanvan, H ;
Bartfai, T ;
Jenck, F ;
Widmer, U ;
Moreau, JL .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 309 (02) :195-200
[8]   Antidepressant-like effects of CP-154,526, a selective CRF(1) receptor antagonist [J].
Mansbach, RS ;
Brooks, EN ;
Chen, YL .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 323 (01) :21-26
[9]  
McCarthy JR, 1999, CURR PHARM DESIGN, V5, P289
[10]  
OLDENDORF W H, 1970, Brain Research, V24, P372, DOI 10.1016/0006-8993(70)90123-X